KR102329175B1 - Bet v 1에 대한 인간 항체 및 이것의 사용 방법 - Google Patents

Bet v 1에 대한 인간 항체 및 이것의 사용 방법 Download PDF

Info

Publication number
KR102329175B1
KR102329175B1 KR1020197036599A KR20197036599A KR102329175B1 KR 102329175 B1 KR102329175 B1 KR 102329175B1 KR 1020197036599 A KR1020197036599 A KR 1020197036599A KR 20197036599 A KR20197036599 A KR 20197036599A KR 102329175 B1 KR102329175 B1 KR 102329175B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antibody
bet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197036599A
Other languages
English (en)
Korean (ko)
Other versions
KR20200012892A (ko
Inventor
제이미 엠. 오렝고
앤드류 제이. 머피
아쇼크 티. 배디테
비샬 카맛
야슈 리우
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020217037411A priority Critical patent/KR102674000B1/ko
Publication of KR20200012892A publication Critical patent/KR20200012892A/ko
Application granted granted Critical
Publication of KR102329175B1 publication Critical patent/KR102329175B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197036599A 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법 Active KR102329175B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217037411A KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US62/513,872 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US62/571,696 2017-10-12
US201862662165P 2018-04-24 2018-04-24
US62/662,165 2018-04-24
PCT/US2018/035366 WO2018222854A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037411A Division KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Publications (2)

Publication Number Publication Date
KR20200012892A KR20200012892A (ko) 2020-02-05
KR102329175B1 true KR102329175B1 (ko) 2021-11-19

Family

ID=62705709

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197036599A Active KR102329175B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
KR1020247018848A Active KR102878718B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
KR1020217037411A Active KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247018848A Active KR102878718B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
KR1020217037411A Active KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Country Status (17)

Country Link
US (3) US10793624B2 (enExample)
EP (1) EP3630814A1 (enExample)
JP (3) JP6963036B2 (enExample)
KR (3) KR102329175B1 (enExample)
CN (1) CN110997713B (enExample)
AU (2) AU2018275657B2 (enExample)
BR (1) BR112019025150B1 (enExample)
CA (1) CA3063588A1 (enExample)
CL (3) CL2019003508A1 (enExample)
CO (1) CO2019013196A2 (enExample)
IL (2) IL298034B2 (enExample)
MX (2) MX2019014430A (enExample)
MY (1) MY198270A (enExample)
NZ (2) NZ782911A (enExample)
PH (1) PH12019550238A1 (enExample)
WO (1) WO2018222854A1 (enExample)
ZA (1) ZA201907513B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2919934T3 (es) 2017-05-05 2022-07-29 Regeneron Pharma Autoinyector y procedimientos de uso relacionados
AU2018275657B2 (en) * 2017-06-01 2022-01-06 Regeneron Pharmaceuticals, Inc. Human antibodies to Bet v 1 and methods of use thereof
EP4175986A1 (en) * 2020-07-01 2023-05-10 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
EP4444348A4 (en) * 2021-12-08 2025-12-03 Iggenix Inc COMBINATIONS FOR ALLERGY THERAPY
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
WO2024251358A1 (en) 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US20250011403A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins
AR134008A1 (es) 2023-10-02 2025-11-26 Regeneron Pharma Sistema de seguridad de dispositivo de administración de fármaco
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US20250255994A1 (en) * 2023-11-29 2025-08-14 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134350A2 (en) 2006-05-18 2007-11-29 Biomay Ag Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases
US20160223563A1 (en) 2013-08-23 2016-08-04 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411594A (en) 1992-10-27 1994-05-24 Biomay Produktions- Und Handelsgesellschaft M.B.H. Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order
JPH08501799A (ja) 1992-12-21 1996-02-27 タノックス バイオシステムズ インコーポレイテッド アレルゲン特異的ＩｇＡモノクローナル抗体及びアレルギー治療のための関連物質
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TWI655207B (zh) * 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
AU2018275657B2 (en) * 2017-06-01 2022-01-06 Regeneron Pharmaceuticals, Inc. Human antibodies to Bet v 1 and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
EP4175986A1 (en) * 2020-07-01 2023-05-10 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134350A2 (en) 2006-05-18 2007-11-29 Biomay Ag Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases
US20160223563A1 (en) 2013-08-23 2016-08-04 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)

Also Published As

Publication number Publication date
AU2022200272A1 (en) 2022-02-10
JP2022174238A (ja) 2022-11-22
AU2018275657B2 (en) 2022-01-06
PH12019550238A1 (en) 2020-10-19
JP6963036B2 (ja) 2021-11-05
CL2021002851A1 (es) 2022-08-19
MY198270A (en) 2023-08-18
CN110997713B (zh) 2024-01-02
IL298034B1 (en) 2024-01-01
JP2020523004A (ja) 2020-08-06
AU2022200272B2 (en) 2024-10-03
BR112019025150B1 (pt) 2022-11-08
KR102674000B1 (ko) 2024-06-11
ZA201907513B (en) 2022-04-28
CL2021002850A1 (es) 2022-06-24
US20210054056A1 (en) 2021-02-25
AU2018275657A1 (en) 2019-12-19
US11767358B2 (en) 2023-09-26
US20240083986A1 (en) 2024-03-14
IL270894A (en) 2020-01-30
KR20210143327A (ko) 2021-11-26
NZ759513A (en) 2022-01-28
EP3630814A1 (en) 2020-04-08
BR112019025150A2 (pt) 2020-06-23
CO2019013196A2 (es) 2020-01-17
JP7162097B2 (ja) 2022-10-27
IL298034B2 (en) 2024-05-01
MX2019014430A (es) 2020-07-14
IL270894B2 (en) 2023-04-01
KR20200012892A (ko) 2020-02-05
JP2021112207A (ja) 2021-08-05
KR102878718B1 (ko) 2025-10-31
IL298034A (en) 2023-01-01
US20180346555A1 (en) 2018-12-06
MX2023000390A (es) 2023-02-13
CL2019003508A1 (es) 2020-06-19
IL270894B (en) 2022-12-01
NZ782911A (en) 2025-08-29
WO2018222854A1 (en) 2018-12-06
CN110997713A (zh) 2020-04-10
JP7458453B2 (ja) 2024-03-29
KR20240096746A (ko) 2024-06-26
CA3063588A1 (en) 2018-12-06
US10793624B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
AU2022200272B2 (en) Human antibodies to Bet v 1 and methods of use thereof
CN110240651B (zh) 针对fel d1的人源抗体及其使用方法
ES2675917T3 (es) Uso médico de anticuerpos humanos de alta afinidad dirigidos contra el receptor humano de IL-4
DK2187964T3 (en) HIGH AFFINE HUMAN ANTIBODIES FOR HUMAN NERVOUS FACTOR
KR101766701B1 (ko) 인간 프로테아제-활성화된 수용체-2에 대한 고친화도 인간 항체들
AU2013305863B2 (en) Human antibodies to GFRalpha3 and methods of use thereof
US11352417B2 (en) Method of treating an allergy with allergen-specific monoclonal antibodies
KR20140069331A (ko) 항-ＥｒｂＢ3 항체 및 이의 용도
EA049718B1 (ru) Фармацевтическая композиция, содержащая антитела человека к bet v 1, и способы ее применения
EA045437B1 (ru) Антитела человека к bet v 1 и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210420

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20210420

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210716

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211007

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211116

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211116

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211117

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 4

End annual number: 4